Precision unveiled: Synergistic genomic landscapes in breast cancer—Integrating single‐cell analysis and decoding drug toxicity for elite prognostication and tailored therapeutics

Globally, breast cancer, with diverse subtypes and prognoses, necessitates tailored therapies for enhanced survival rates. A key focus is glutamine metabolism, governed by select genes. This study explored genes associated with T cells and linked them to glutamine metabolism to construct a prognostic staging index for breast cancer patients for more precise medical treatment.

[1]  R. Pestell,et al.  The Role and Therapeutic Targeting of CCR5 in Breast Cancer , 2023, Cells.

[2]  Lei Zhang,et al.  Mitochondrial Control for Healthy and Autoimmune T Cells , 2023, Cells.

[3]  Zhong Ji,et al.  HOPX is a tumor-suppressive biomarker that corresponds to T cell infiltration in skin cutaneous melanoma , 2023, Cancer Cell International.

[4]  Shenmin Zhang,et al.  Machine learning immune-related gene based on KLRB1 model for predicting the prognosis and immune cell infiltration of breast cancer , 2023, Frontiers in Endocrinology.

[5]  Cong Yu,et al.  Integrated spatial transcriptome and metabolism study reveals metabolic heterogeneity in human injured brain , 2023, Cell reports. Medicine.

[6]  Y. Suh,et al.  Structural Congeners of Izenamides Responsible for Cathepsin D Inhibition: Insights from Synthesis-Derived Elucidation , 2023, Marine drugs.

[7]  Pu Xia,et al.  Human leukocyte antigen and tumor immunotherapy (Review) , 2023, International journal of oncology.

[8]  Q-G Yang,et al.  A Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer Therapy , 2023, Advanced science.

[9]  S. Mou,et al.  An integrated co-expression network analysis reveals novel genetic biomarkers for immune cell infiltration in chronic kidney disease , 2023, Frontiers in Immunology.

[10]  B. George,et al.  Hyperactivation of p21-Activated Kinases in Human Cancer and Therapeutic Sensitivity , 2023, Biomedicines.

[11]  K. Nephew,et al.  Glutamine metabolism in breast cancer and possible therapeutic targets. , 2023, Biochemical pharmacology.

[12]  Jenifer R Prosperi,et al.  Proteins Found in the Triple-Negative Breast Cancer Secretome and Their Therapeutic Potential , 2023, International journal of molecular sciences.

[13]  C. Liang,et al.  The role of glutamine metabolism in castration-resistant prostate cancer , 2023, Asian journal of andrology.

[14]  Keda Yu,et al.  Combined Single‐Cell and Spatial Transcriptomics Reveal the Metabolic Evolvement of Breast Cancer during Early Dissemination , 2023, Advanced science.

[15]  Shiheng Wang,et al.  The efficacy and safety of acupuncture and moxibustion for breast cancer lymphedema: a systematic review and network meta-analysis , 2023, Gland surgery.

[16]  H. Cao,et al.  Role of androgen receptor signaling pathway-related lncRNAs in the prognosis and immune infiltration of breast cancer , 2022, Scientific Reports.

[17]  N. Zhou,et al.  Comprehensive analyses of one-carbon metabolism related genes and their association with prognosis, tumor microenvironment, chemotherapy resistance and immunotherapy in lung adenocarcinoma , 2022, Frontiers in Molecular Biosciences.

[18]  P. Kronqvist,et al.  Varying outcomes of triple-negative breast cancer in different age groups–prognostic value of clinical features and proliferation , 2022, Breast Cancer Research and Treatment.

[19]  H. R. Frost,et al.  SPECK: an unsupervised learning approach for cell surface receptor abundance estimation for single-cell RNA-sequencing data , 2022, bioRxiv.

[20]  E. Koc,et al.  Role of mitochondrial translation in remodeling of energy metabolism in ER/PR(+) breast cancer , 2022, Frontiers in Oncology.

[21]  R. Kiyama,et al.  Novel estrogen-responsive genes (ERGs) for the evaluation of estrogenic activity , 2022, PloS one.

[22]  Q. Hao,et al.  Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer , 2022, Frontiers in Immunology.

[23]  Guo Huang,et al.  Identification of pyroptosis related subtypes and tumor microenvironment infiltration characteristics in breast cancer , 2022, Scientific Reports.

[24]  C. Ficorella,et al.  Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status , 2022, Cancers.

[25]  Yi-lian Pan,et al.  Integrative Dissection of Novel Lactate Metabolism-Related Signature in the Tumor Immune Microenvironment and Prognostic Prediction in Breast Cancer , 2022, Frontiers in Oncology.

[26]  Cheng Zeng,et al.  A narrative review of five multigenetic assays in breast cancer , 2022, Translational cancer research.

[27]  Zhaomin Yao,et al.  Feature Selection of OMIC Data by Ensemble Swarm Intelligence Based Approaches , 2022, Frontiers in Genetics.

[28]  Dalin Li,et al.  Quality of Life in Patients with Breast Cancer following Breast Conservation Surgery: A Systematic Review and Meta-Analysis , 2022, Journal of healthcare engineering.

[29]  M. Xia,et al.  S100A4/TCF Complex Transcription Regulation Drives Epithelial-Mesenchymal Transition in Chronic Sinusitis Through Wnt/GSK-3β/β-Catenin Signaling , 2022, Frontiers in Immunology.

[30]  Min Zhao,et al.  Decode the Stable Cell Communications Based on Neuropeptide-Receptors Network in 36746 Tumor Cells , 2021, Biomedicines.

[31]  Jiansong Wang,et al.  Estrogen receptor—positive breast cancer survival prediction and analysis of resistance–related genes introduction , 2021, PeerJ.

[32]  Y. Liu,et al.  The role of B7-H3 in tumors and its potential in clinical application. , 2021, International immunopharmacology.

[33]  Eisha Tir Razia,et al.  Targeted Inhibition of Fibroblast Growth Factor Receptor 1-GLI Through AZD4547 and GANT61 Modulates Breast Cancer Progression , 2021, Frontiers in Cell and Developmental Biology.

[34]  T. Phan,et al.  Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q , 2021, Cancers.

[35]  N. Phan,et al.  Potential Therapeutic and Prognostic Values of LSM Family Genes in Breast Cancer , 2021, Cancers.

[36]  K. Fisher,et al.  Deregulation of HLA-I in cancer and its central importance for immunotherapy , 2021, Journal for ImmunoTherapy of Cancer.

[37]  Jie Zhao,et al.  CELF2 is a candidate prognostic and immunotherapy biomarker in triple‐negative breast cancer and lung squamous cell carcinoma: A pan‐cancer analysis , 2021, Journal of cellular and molecular medicine.

[38]  J. Zou,et al.  Identification of a Prognostic Index Based on a Metabolic-Genomic Landscape Analysis of Hepatocellular Carcinoma (HCC) , 2021, Cancer management and research.

[39]  T. Meshel,et al.  Continuous Inflammatory Stimulation Leads via Metabolic Plasticity to a Prometastatic Phenotype in Triple-Negative Breast Cancer Cells , 2021, Cells.

[40]  N. Barlev,et al.  Proteomic Analysis of Zeb1 Interactome in Breast Carcinoma Cells , 2021, Molecules.

[41]  T. Kohno,et al.  Distribution of genetic alterations in high-risk early-stage cervical cancer patients treated with postoperative radiation therapy , 2021, Scientific Reports.

[42]  D. Teegarden,et al.  Vitamin D regulation of energy metabolism in cancer , 2021, British journal of pharmacology.

[43]  Zhitong Bing,et al.  Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy , 2021, Neoplasia.

[44]  Lin Qin,et al.  Application of single-cell RNA sequencing technology in liver diseases: a narrative review , 2021, Annals of translational medicine.

[45]  Linda V. Sinclair,et al.  A glutamine ‘tug-of-war’: targets to manipulate glutamine metabolism for cancer immunotherapy , 2021, Immunotherapy advances.

[46]  Amy L. Olex,et al.  Regulatory T Cells Support Breast Cancer Progression by Opposing IFN-γ-Dependent Functional Reprogramming of Myeloid Cells. , 2020, Cell reports.

[47]  M. Pisano,et al.  Gestational folate deficiency alters embryonic gene expression and cell function. , 2020, Differentiation; research in biological diversity.

[48]  Jianying Zhang,et al.  SNRPD1 confers diagnostic and therapeutic values on breast cancers through cell cycle regulation , 2020, Cancer Cell International.

[49]  C. Peters,et al.  Cathepsin D deficiency in mammary epithelium transiently stalls breast cancer by interference with mTORC1 signaling , 2020, Nature Communications.

[50]  Xuan Zhu,et al.  High expression of UNC5B enhances tumor proliferation, increases metastasis, and worsens prognosis in breast cancer , 2020, Aging.

[51]  Yanfeng Gao,et al.  Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR , 2020, Cell Communication and Signaling.

[52]  Yuanwen Chen,et al.  microRNA‐128‐3p overexpression inhibits breast cancer stem cell characteristics through suppression of Wnt signalling pathway by down‐regulating NEK2 , 2020, Journal of cellular and molecular medicine.

[53]  Hongbo Zhu,et al.  HOPX Is an Epigenetically Inactivated Tumor Suppressor and Overexpression of HOPX Induce Apoptosis and Cell Cycle Arrest in Breast Cancer , 2020, OncoTargets and therapy.

[54]  Qian Li,et al.  HnRNPR-CCNB1/CENPF axis contributes to gastric cancer proliferation and metastasis , 2019, Aging.

[55]  Vo Truong Nhu Ngoc,et al.  The Effects of Adipocytes on the Regulation of Breast Cancer in the Tumor Microenvironment: An Update , 2019, Cells.

[56]  S. Samuel,et al.  The “Yin and Yang” of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers , 2018, Cancers.

[57]  Z. Dai,et al.  Identification of long non-coding RNA signatures in triple-negative breast cancer , 2018, Cancer Cell International.

[58]  Wei-Qiang Gao,et al.  CCL5-deficiency enhances intratumoral infiltration of CD8+ T cells in colorectal cancer , 2018, Cell Death & Disease.

[59]  Jae-Eun Ryu,et al.  Expression of the glutamine metabolism‐related proteins glutaminase 1 and glutamate dehydrogenase in canine mammary tumours , 2018, Veterinary and comparative oncology.

[60]  R. Natrajan,et al.  Splicing dysregulation as a driver of breast cancer , 2018, Endocrine-related cancer.

[61]  L. Jones,et al.  Mechanisms of immune evasion in breast cancer , 2018, BMC Cancer.

[62]  Tingting Li,et al.  Polo-like kinase 1 coordinates biosynthesis during cell cycle progression by directly activating pentose phosphate pathway , 2017, Nature Communications.

[63]  A. Morrison,et al.  Mutations in folate transporter genes and risk for human myelomeningocele , 2017, American journal of medical genetics. Part A.

[64]  W. Cao,et al.  Correlations of EZH2 and SMYD3 gene polymorphisms with breast cancer susceptibility and prognosis , 2017, Bioscience reports.

[65]  S. Manoir,et al.  Transcription Factor Networks derived from Breast Cancer Stem Cells control the immune response in the Basal subtype , 2017, Scientific Reports.

[66]  Yanli Wang,et al.  PubChem BioAssay: 2017 update , 2016, Nucleic Acids Res..

[67]  M. Wasik,et al.  13C MRS and LC–MS Flux Analysis of Tumor Intermediary Metabolism , 2016, Front. Oncol..

[68]  Zhipeng Wang,et al.  Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer , 2016, Tumor Biology.

[69]  E. Seki,et al.  Exosome Migration Inhibitory Factor as a Marker and Therapeutic Target for Pancreatic Cancer. , 2016, Gastroenterology.

[70]  Minghui Zhang,et al.  Overexpression of G6PD is associated with high risks of recurrent metastasis and poor progression-free survival in primary breast carcinoma , 2015, World Journal of Surgical Oncology.

[71]  Wei-Qiang Gao,et al.  CCL5-Mediated Th2 Immune Polarization Promotes Metastasis in Luminal Breast Cancer. , 2015, Cancer research.

[72]  Michael L. Wang,et al.  CD4+ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma , 2015, Oncotarget.

[73]  Joon Jeong,et al.  Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer , 2015, Journal of pathology and translational medicine.

[74]  S. Varambally,et al.  Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer , 2015, Oncotarget.

[75]  D. Sohn,et al.  Heme oxygenase-1 promotes tumor progression and metastasis of colorectal carcinoma cells by inhibiting antitumor immunity , 2015, Oncotarget.

[76]  N. Borcherding,et al.  Bone Marrow Stromal Antigen 2 (BST-2) DNA Is Demethylated in Breast Tumors and Breast Cancer Cells , 2015, PloS one.

[77]  M. Koutsilieris,et al.  The role of the insulin-like growth factor-1 system in breast cancer , 2015, Molecular Cancer.

[78]  Jason M. Held,et al.  RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth , 2014, Oncotarget.

[79]  I. Pinchuk,et al.  Chronic Macrophage Migration Inhibitory Factor Exposure Induces Mesenchymal Epithelial Transition and Promotes Gastric and Colon Cancers , 2014, PloS one.

[80]  F. Yu,et al.  MiR-27 as a Prognostic Marker for Breast Cancer Progression and Patient Survival , 2012, PloS one.

[81]  Yu Liang,et al.  S100A4 promotes invasion and angiogenesis in breast cancer MDA-MB-231 cells by upregulating matrix metalloproteinase-13. , 2012, Acta biochimica Polonica.

[82]  A. Harris,et al.  Endothelial cell metabolism and implications for cancer therapy , 2012, British Journal of Cancer.

[83]  K. Yamashita,et al.  Cancer specific promoter CpG Islands hypermethylation of HOP homeobox (HOPX) gene and its potential tumor suppressive role in pancreatic carcinogenesis , 2012, BMC Cancer.

[84]  B. Ramaswamy,et al.  Epigenetic Therapy in Breast Cancer , 2011, Current breast cancer reports.

[85]  M. Musaviun,et al.  Molecular Characterization of Cosenza Mutation among Patients with Glucose-6-Phosphate Dehydrogenase Deficiency in huzestan Province, Southwest Iran , 2011, Iranian journal of medical sciences.

[86]  Y. Wan,et al.  Homeodomain only protein is required for the function of induced regulatory T cells in dendritic cell-mediated peripheral T cell unresponsiveness , 2010, Nature Immunology.

[87]  Garrett M Morris,et al.  Using AutoDock for Ligand‐Receptor Docking , 2008, Current protocols in bioinformatics.

[88]  S. Knechtle,et al.  CXCR3‐mediated T‐cell chemotaxis involves ZAP‐70 and is regulated by signalling through the T‐cell receptor , 2007, Immunology.

[89]  M. Salmon,et al.  A Chemokine-Dependent Stromal Induction Mechanism for Aberrant Lymphocyte Accumulation and Compromised Lymphatic Return in Rheumatoid Arthritis , 2005, The Journal of Immunology.

[90]  M. Campa,et al.  Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression. , 2016, Cancer discovery.

[91]  O. I. Epifanova,et al.  Mechanisms underlying the differential sensitivity of proliferating and resting cells to external factors. , 1977, International review of cytology. Supplement.